ATOS Atossa Therapeutics Inc: Net earnings per share for the last 12 months

Public company logo of Atossa Pharma (ATOS)

Atossa Therapeutics (ATOS) is striving for pricing power through Endoxifen, which is transforming hormonal care for breast cancer. This chart of the share price reflects an EPS of -11.00 as the company penetrates the women's oncology market through innovation. Business prospects rely on the success of clinical trials and sufficient liquidity to cover testing costs.

Atossa Therapeutics Inc (ATOS): Earnings per share for the last twelve months from 02/11/2024 to 11/13/2026

Financial and market metric breakdowns for Atossa (ATOS)

- price and consensus price forecast:
Market Price atossatherapeutics.com|ATOS - Price Target Chart
- company stock capitalization data:
Market Valuation Atossa Therapeutics Inc|ATOS - Enterprise Value
- book capitalization data:
Net Asset Value per Share Atossa Therapeutics|ATOS - Company Book Value|Capitalization to Book Value Ratio atossatherapeutics.com|ATOS - Company Total Assets
- company total debt and liquidity indicators:
Total Debt to Capital Atossa Therapeutics|ATOS - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Atossa Pharma|ATOS - Company Debts|Debts to Book Value Atossa Therapeutics Inc|ATOS - Company Long-Term Debt|Short-Term Debt Volume Atossa Therapeutics|Interim Coverage Ratio atossatherapeutics.com
- net income and valuation ratios data:
ATOS - Net Profit|Projected Future Earnings Atossa Therapeutics|ATOS - Price to Earnings Ratio|Future Price to Earnings Multiple Atossa Therapeutics Inc|ATOS - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Atossa Therapeutics Inc|ATOS - Operating profit EBITDA|Earnings per share for the trailing year Atossa Therapeutics|ATOS - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months atossatherapeutics.com|ATOS - Earnings per share growth in current year|Expected earnings per share trend next year Atossa Therapeutics
Initial company analysis:ATOS, atossatherapeutics.com
Mass-produced product of Atossa Therapeutics Inc

Atossa Therapeutics (ATOS) invests in biochemical research to combat breast cancer. The rolling year earnings per share trend reflects the efficiency of these expenditures, comparing current financial results with the same period last year. By analyzing the EPS YoY volatility over the last 12 months, an investor can discern the real rate of capital growth. High volatility in this metric directly impacts the issuer's market capitalization.

Competitor analysis

Net earnings per one share for the last twelve months merus.nl|Immutep (IMMP) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months Anixa Biosciences|CNTX (Context Therapeutics Inc) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Mersana MRSN|Earnings per share for the last twelve months BriaCell Therapeutics (BCTX)|essapharma.com - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) QTI (QT Imaging)